Lexicon Pharmaceuticals Announces Departure of President and Chief Operating OfficerGlobeNewsWire • Monday
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 DiabetesGlobeNewsWire • 09/10/24
Lexicon Pharmaceuticals to Participate in Upcoming September Investor ConferencesGlobeNewsWire • 09/03/24
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial PortfolioGlobeNewsWire • 08/13/24
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education SpecialistsGlobeNewsWire • 08/07/24
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory SuccessSeeking Alpha • 08/03/24
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/01/24
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024GlobeNewsWire • 07/25/24
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and DirectorGlobeNewsWire • 07/08/24
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes AssociationGlobeNewsWire • 06/19/24
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes AssociationGlobeNewsWire • 06/14/24
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two DecadesBusiness Wire • 05/29/24
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024GlobeNewsWire • 05/29/24
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection FractionGlobeNewsWire • 05/14/24
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024GlobeNewsWire • 05/09/24
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/02/24
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/02/24